Toggle Main Menu Toggle Search

Open Access padlockePrints

Can Digital Mobility Assessment Enhance the Clinical Assessment of Disease Severity in Parkinson’s Disease?

Lookup NU author(s): Dr Cameron KirkORCiD, Dr Rana RehmanORCiD, Dr Brook Galna, Dr Lisa AlcockORCiD, Professor Lynn RochesterORCiD, Dr Silvia Del DinORCiD, Professor Alison Yarnall

Downloads


Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).


Abstract

Background: Real-world walking speed (RWS) measured using wearable devices has the potential to complement the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS III) for motor assessment in Parkinson’s disease (PD). Objective: Explore cross-sectional and longitudinal differences in RWS between PD and older adults (OAs), and whether RWS was related to motor disease severity cross-sectionally, and if MDS-UPDRS III was related to RWS, longitudinally. Methods: 88 PD and 111 OA participants from ICICLE-GAIT (UK) were included. RWS was evaluated using an accelerometer at four time points. RWS was aggregated within walking bout (WB) duration thresholds. Between-group-comparisons in RWS between PD and OAs were conducted cross-sectionally, and longitudinally with mixed effects models (MEMs). Cross-sectional association between RWS and MDS-UPDRS III was explored using linear regression, and longitudinal association explored with MEMs. Results: RWS was significantly lower in PD (1.04m/s) in comparison to OAs (1.10 m/s) cross-sectionally. RWS significantly decreased over time for both cohorts and decline was more rapid in PD by 0.02 m/s per year. Significant negative relationship between RWS and the MDS-UPDRS III only existed at a specific WB threshold (30 to 60 seconds, β = -3.94 points, P = 0.047). MDS-UPDRS III increased significantly by 1.84 points per year, which was not related to change in RWS. Conclusions: Digital mobility assessment of gait may add unique information to quantify disease progression remotely, but further validation in research and clinical settings is needed.


Publication metadata

Author(s): Kirk C, Rehman R, Galna B, Alcock L, Ranciati S, Palmerini L, Garcia-Aymerich J, Hansen C, Schaeffer E, Berg D, Maetzler W, Rochester L, Del Din S, Yarnall A

Publication type: Article

Publication status: Published

Journal: Journal of Parkinson's Disease

Year: 2023

Volume: 13

Issue: 6

Pages: 999-1009

Online publication date: 31/07/2023

Acceptance date: 03/07/2023

Date deposited: 09/08/2023

ISSN (print): 1877-7171

ISSN (electronic): 1877-718X

Publisher: IOS Press

URL: https://doi.org/10.3233/JPD-230044

DOI: 10.3233/JPD-230044

Data Access Statement: The data supporting these findings is available on request from the corresponding author


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
820820
BRC
European Union Horizon 2020
European Federation of Pharmaceutical Industries and Associations (EFPIA)
G-1301
J-0802Parkinson`s UK (formerly Parkinson`s Disease Society)
nnovative Medicines Initiative 2 Joint Undertaking (JU)
Parkinson’s UK
NIHR
Wellcome Trust

Share